Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model

Publisher Website
Google Scholar
Abstract
Peptide receptor scintigraphy with [111In‐DTPA0]octreotide (a stabilized radiolabeled somatostatin (SS) analogue, OctreoScan®) is widely used for the visualization and staging of somatostatin receptor‐positive tumors. The application of likewise somatostatin analogues as vehicle for the deliverance of radionuclides to somatostatin receptor‐positive targets are now in use for peptide receptor‐targeted radionuclide therapy (PRRT). Currently preclinical and clinical investigation are ongoing trying to find the optimal combination of radionuclide and ligand. The anti‐tumoral effects of such combinations, like [90Y‐DOTA°, Tyr3]octreotide and [177Lu‐DOTA°, Tyr3]octreotate, on SSR‐positive solid tumors have been reported. In this study we present the anti‐tumor effects of 177Lu‐DOTA‐tate on: a) a single SSR‐positive cell model and b) on a SSR‐positive tumor in a rat liver micrometastatic model, mimicking disseminated disease. 177Lu‐DOTA‐tate showed anti‐tumoral effects in both cases and significant survival in the PRRT‐treated rats. 177Lu‐DOTA‐tate is a very promising new treatment modality for SSR‐positive tumors, including disseminated disease.